SKNV, Pompano Beach, FL
Is SKNV registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B.
Does SKNV hold a Florida pharmacy license?
The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH29976 for SINCERUS FLORIDA, LLC (dba SKNV), POMPANO BEACH, status Clear and PH29905 for SINCERUS FLORIDA, LLC (dba SKNV), POMPANO BEACH, status Vol Relinquish. The Colorado State Board of Pharmacy also lists nonresident license OSP 7338 for SKNV, Pompano Beach, FL, status Expired, as of Nov 15, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0003722 for SKNV, POMPANO BEACH, FL, status INACTIVE, as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0000048 for Sincerus Florida, LLC (dba SKNV), POMPANO BEACH, FL, status Active and license A9-0002440 for Sincerus Florida, LLC (dba SKNV), POMPANO BEACH, FL, status Expired, as of Nov 10, 2026.
Has SKNV had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Sep 16, 2025) and 3 FMD-145 letters (Nov 16, 2020, Sep 30, 2024 and Apr 22, 2026) for SKNV. State board actions: no Florida Board of Pharmacy action on licenses PH29976 and PH29905 or under this exact name and city was found in the board’s enforcement list for pharmacy permits (actions dated Sep 19, 1980 to Nov 10, 2026) on Nov 15, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- SKNV
- Former names FDA gives
- Sincerus Florida LLC
- Location
- Pompano Beach, FL
- Type as FDA labels it
- 503B
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 3
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- May 29, 2026
- FDA Data Dashboard inspections
- 5 inspections: 1 OAI, 4 VAI; 6 published Form 483s
- Form 483 text on this page
- 5 Form 483s, 21 observations
- State board records
- License found: PH29976, Clear; PH29905, Vol Relinquish
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as SKNV (formerly Sincerus Florida LLC), a 503B facility, with 7 dated actions.
| Document | |||
|---|---|---|---|
| May 29, 2026 | Form 483 | 483 Issued 05/29/2026 | fda.gov |
| Apr 22, 2026 | FMD-145 letter | FMD-145 Letter Issued 04/22/2026 | Not linked by FDA |
| Sep 16, 2025 | Untitled letter | Untitled Letter Issued 09/16/2025 | fda.gov |
| Mar 6, 2025 | Form 483 | 483 Issued 03/06/2025 | fda.gov |
| Sep 30, 2024 | FMD-145 letter | FMD-145 Letter Issued 09/30/2024 | Not linked by FDA |
| May 23, 2024 | Form 483 | 483 Issued 05/23/2024 | FDA copy (archived) |
| Nov 16, 2020 | FMD-145 letter | FMD-145 Letter Issued 11/16/2020 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists SKNV, Pompano Beach, FL (FEI number 3012384835), matched to this page by exact name, city and state. It lists 5 inspections: 1 OAI, 4 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Mar 6, 2025 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3012384835 | 1263272 |
| May 23, 2024 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3012384835 | 1229212 |
| Sep 17, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3012384835 | 1065810 |
| Jun 26, 2017 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3012384835 | 1017462 |
| Jul 15, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3012384835 | 986127 |
Form 483s FDA has published for this site
- May 29, 2026: Form 483 to SKNV, published Jul 22, 2026. fda.gov
- Mar 6, 2025: Form 483 to SKNV, published Mar 28, 2025. fda.gov
- May 23, 2024: Form 483 to SKNV, published Aug 8, 2024. fda.gov
- Sep 17, 2018: Form 483 to SKNV, published Apr 30, 2019. fda.gov
- Jan 8, 2018: Form 483 to SKNV, published Jan 17, 2024. fda.gov
- Aug 22, 2016: Form 483 to SKNV, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 21 numbered observations in all, across 5 inspections ending Jun 26, 2017 to May 29, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection May 18, 2026 to May 29, 2026: 7 observations
- Firm on the cover
- Sincerus Florida, LLC dba SKNV, 3265 W Mcnab Rd . & 2030 W. Mcn ab Rd. C ARR 05/29/26, Pompano Beach, FL 33069
- FEI number
- 3012384835
- Establishment type on the cover
- Outsourcing Facility C.l't~ ~ CJ~/.;J.q/
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard, 503B list
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process. Specifically,
I) The following deficiencies were identified during the review of the Smoke Visualization studies conducted in October 2025 for the <Redacted B4> ISO 5 Laminar Air Flow Hood (LAFH) (Equipment 10: 00167) in which sterile 2 GM Magnesium Sulfate in 5% Dextrose 50 ml Bag Injection is produced:
a.
Processes which occur during routine operations, such as sanitizing the Magnesium Sulfate vial stoppers and drawing 4 mL from the vial using a syringe, sanitizing each 5% Dextrose Bag Injection Port, injecting the contents of the syringe into the Dextrose bag, and placing an IV seal on each IV port injected, were not simulated during the Dynamic Smoke Study.
b.
During the Dynamic Smoke Study, the smoke was positioned away from the technician and the area where the technician was performing operations within the LAFH; as a result, the airflow pattern over the operations could not be visualized.
C. ...
Observation 2
Equipment and utensils are not cleaned and maintained at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product. Specifically,
The following deficiencies were identified during the facility walkthrough on 05/ 18/2026 within the <Redacted B4> ISO 5 Laminar Air Flow Hood (LAFH) (Equipment ID: 00167) which is used for producing sterile drug product 2 GM Magnesium Sulfate in 5% Dextrose 50 m L Bag Injection:
1) Scratches were observed on the HEPA filter grate, and the grate was observed to be curved inward (indented) on the left side of the ISO 5 LAFH. Additionally, similar inward curve/ indentation of the HEPA filter grate was observed in the Dynamic Smoke Study video which was conducted in Ocrober 2025; 2 GM Magnesium Sulfate in 5% Dextrose 50 mL Bag Injection Lots 74946 (BUD: 08JAN26) and 75101 (BUD: 24JAN26) were compounded in the ISO 5 LAFH on <Redacted B4> and <Redacted B4>, respectively.
2) Cracks were observed on the interior of the plexiglass side panel on the right side of the ISO 5 LAFH. ...
Observation 3
Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet appropriate statistical quality control criteria as a condition for their approval and release. Specifically,
The firm's Quality Unit does not perform independent Acceptable Quality Limit (AQL) sampling and testing of finished sterile drug products following 100% manual visual inspection. The firm's procedure # SC-03 ·•Final Visual Inspection of Compounded Sterile Preparations (CSPs)" does not include instructions for Quality Unit AQL sampling and testing. Without independent AQL testing by the Quality Unit, there is no objective, statistically sound evaluation of whether released product is essentially free of visible defects. ...
Observation 4
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. Specifically,
The firm's procedure# SC-03 "Final Visual Inspection of Compounded Sterile Preparations (CSPs)" does not include instructions for creation and characterization of the defects to be used, including the range of sizes to be used in, and instructions for the qualification of the Visual Inspection Qualification (defect) <Redacted B4>. Specifically, the defect <Redacted B4> designed on O5NOV2025 and used to qualify manual visual inspectors is inadequate in that the particulates contained in the defect <Redacted B4> are of unknown size. No threshold studies (e.g., probability of detection studies) have been performed to determine whether the particulates in the <Redacted B4> represent the range of defect sizes likely to be encountered in the finished sterile drug product, and whether trained personnel can reproducibly detect them. ...
Observation 5
Written procedures are not established and followed for the cleaning and maintenance of equipment, including, utensils, used in the manufacture. processing, packing or holding of a drug product. Specifically,
The contact times maintained during the cleaning and disinfecting of the Cleanroom Suite and the ISO 5 LAFH, used for producing sterile drug product 2 GM Magnesium Sulfate in 5% Dextrose 50 mL Bag Injection Lot 74946 (Compounding Date: <Redacted B4>) and Lot 7510 (Compounding Date: <Redacted B4> are not documented. The firm's procedure# SC-I7 '·Sterile Compounding Area Cleaning and Disinfecting" specifies a required minimum contact time of <Redacted B4> for <Redacted B4> and <Redacted B4> and a minimum of <Redacted B4> for <Redacted B4> <Redacted B4> however.the contact times are not recorded in the compounding batch records or cleaning logs and the firm 's procedure SC-17 does not require documentation of the contact time.
Observation 6
The responsibilities and procedures applicable to the quality control unit are not in writing or fully followed. Specifically.
1) No assessment of retain samples, batch records, and laboratory testing data were conducted at the time of receipt of the below listed complaints, as required by the firms procedure# QA-IO ··customer Complaints Management" Steps 7.6.1 and 7.6.3 which states that Quality investigates the complaint to determine if the compounded product may have resulted in a Quality Non-Adverse Event, Adverse Event, or Serious Adverse Event and Quality checks retain samples, batch record, and laboratory testing data for the reported lots, respectively.
a.
Complaint# CR25-540 (SKU: 03 1098; Product: Holixia Solution (Minoxidil 7%/Progesterone 0.1 %; Lot# 71065): Patient Complaint Description: Getting severe migraines and causing scalp to burn/itch.
b. Complaint# CR25-389 (SKU: 031098, Product: Holixia Solution, Lot# 71065): Patient Complaint Description: Patient experienced itchiness and redness on the skin/itchy scalp.
c. ...
Observation 7
Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not established, written or followed. Specifically,
The firm's non-sterile topical drug products and <Redacted B4> Water, used in producing the non-sterile drug products, are not routinely tested for objectionable microorganisms such as Burkholderia cepacia complex (BCC) . <Redacted B4> Water is used as an ingredient in the formulation of topical drug products including, but not limited to, Clobetasol Propionate 0.05%/Niacinamide 4% Solution and Hydrocortisone 0.5%/ Hydroquinone 8%/Tretinoin 0.025% Emulsion. Additionally, the firm 's procedure# TM-47 "Microbial Analysis of <Redacted B4> Water at SKNV FL" does not require testing of the <Redacted B4> Water for BCC.
0.025% Emulsion. Additionally, the firm 's procedure# TM-47 "Microbial Analysis o((b) (4) Water at SKNV FL" does not require testing ofthe(b) (4) Water for BCC.
Inspection Feb 13, 2025 to Mar 6, 2025: 3 observations
- Firm on the cover
- SKNV, 3265 W Mcnab Rd, Pompano Beach, FL 33069-4807
- FEI number
- 3012384835
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 555 Winderley Place, Suite 200 Maitland, FL 32751
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
A. On 09/18/24 in anticipation of your production batch of Magnesium Sulfate for Injection, Lot <Redacted B4> BUD 11/03/24, your quality unit reviewed and identified a typical behavior in the different pressure readings in the ISO 7 ante-room. Specifically, your quality unit identified 19 occurrences where differential pressure values were as out of specification on 09/18/24 from around 10:18am -10:43am and 3:45pm -5:24pm; the readings were below and above the specification of <Redacted B4> water, ranging from -0.04 -0.25. Your quality unit attributed the abenant findings to pre-operation activities and later determined the HEPA motor as a contributor to the failures. Your firm was unable to provide an investigation, or equivalent documentation, which would include product impact assessment, to capture information on the events with supporting scientific justification. This lot was ultimately released for distribution.
B. On 06/13/24, your team conducted a media fill where a microbiologic personnel sample (garb) yielded the presence of Priestia flexa. ...
Observation 2
Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.
Specifically, Document Number N-227, GMP Cleaning, Revision 00, fails to provide directions for deactivating, decontaminating, and cleaning of production and processing areas and equipment used to produce hazardous drugs.
Observation 3
The container of your outsourcing facility's drug products does not include information required by section 503B(a)(10)(B) of the Federal Food, Drug and Cosmetic Act (FD&CAct).
Specifically,
A. Your firm's magnesium sulfate injection product container does not include:
1. Information to facilitate adverse event reporting: www.fda.gov/medwatch and 1- 800-
FDA- 1088;
2. Directions for use, including, as appropriate, dosage and administration.
B. The containers for your firm's non-sterile compounded products, including Harviva HP Solution, Holixia Solution, Melondis Emulsion, Medorfa HP Emulsion, Nobela Cream, Aluris Cream, Nolira Ointment, Aluris Plus Cream, and Rositara Gel, do not include:
1. Directions for use, including, as appropriate, dosage and administration. More specifically, the route of administration is not included.
specifically, the route of administration is not included.
Inspection May 13, 2024 to May 23, 2024: 2 observations
- Firm on the cover
- SKNV, 3265 W Mcnab Rd, Pompano Beach, FL 33069-4807
- FEI number
- 3012384835
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 60 Eighth Street NE Atlanta, GA 30309
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
The container of your outsourcing facility's drug products does not include information required by section 503B(a)(10)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Specifically, your containers do not include the following information:
a) Information to facilitate adverse event reporting: <www.fda.gov/medwatch> and 1-800-FDA-1088
b) Directions for use, including, as appropriate, dosage and administration.
Observation 2
Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.
Specifically, the following products were compounded and not identified on your report dated December 2023:
a) 031041 FLUOCINOLONE ACETONIDE 0.01% / MINOXIDIL 5% / TRETINOIN 0.025% SOLUTION with NDC # 72934-4348-08
b) 351036 CICLOPIROX 0.77% / SALICYLIC ACID 2% Shampoo with NDC # 72934-7425-06
c) 201070 BENZOCAINE 20% / LIDOCAINE 10% / TETRACAINE 10% Cream with NDC # 72934 -2406-04
Inspection Aug 30, 2018 to Sep 17, 2018: 6 observations
- Firm on the cover
- Sincerus Florida, LLC, 3265 W McNab Rd, Pompano Beac h, FL 33069-4807
- FEI number
- 3012384835
- Establishment type on the cover
- Outsourcing Facility 1his document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.
- FDA district office on the cover
- 555 Winderley Place, Su ite 200 Ma itland, FL 32 751 (407
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.
Specifically, non-pharmaceutical grade components are used in the formulation of non-sterile duty products.
Your firm uses <Redacted B4> Solution in the formulation of your non-sterile drug product, your firm did not provide any documentation supporting this component, which is not USP rade. Your firm does not conduct any microbial testing on any drug products that uses <Redacted B4>or
Observation 2
Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.
Specifically, your fnm has failed to perform release testing for potency on each batch of drug product produced at your facility. Examples include, but are not limited to the following:
Product 031101- Ketoconazole 2% / Minoxidil 7% I Tretinoin 0.05%, Lot 031101AHBGCABI@14, BUD 08/15/18 Product 041013- Betamethasone Dipropionate 0.05% I Menthol 2% I Pramoxine HCL 1% / Tranilast 0.5%, Lot 041013AICICABI@14, BUD 09/27/18 Product 141030- Hydroquinone 8%, Lot 141030AJAFCABI@14, BUD 10/05/18
Product 201017- Lidocaine 23%/ Plilocaine 5% (Oleabase), Lot 201017AIBGCABI@l , BUD 02/12/19
Observation 3
The in process control procedures were deficient in that they did not include an examination of the adequacy of mixing to assure uniformity and homogeneity.
Specifically, your firm failed to validate your current formulaiy procedures are in accordance with your reference procedures to ensure homogeneity and blend uniformity are obtained.
Observation 4
There is no written testing program designed to assess the stability characteristics of drug products.
Specifically, your firm has not performed stability testing on any drug product to ensure the shelf-life of the drug products. Examples include, but are not limited to:
Observation 5
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been aheady distributed.
Specifically, multiple complaint investigations into adverse events lacked a thorough investigation into the root cause for the complaint. Examples include, but are not limited to:
Complaint 18-52 Five patients experienced redness dming use of Product 201019-Lidocaine 23%ffetracaine 7%, Lot 201019ABAECABI@6, BUD 05/09/1 8. There was no root cause or potential root cause identified.
Complaint 18-84- Four patients experienced a rash after use of Product 011009 -Niacinamide 4%ffrentinoin 0.05%, Lot 011009BBCBCABH@8, BUD 12/21117. There was no root cause or potential root cause identified.
Complaint 18-138- Multiple patients experienced redness, hives, itching, or swelling within five (5) minutes of applying Product 201016- Lidocaine 7%/Tetracaine 7%, Lot 201016ADCJCABI@2, BUD 09/25/18. There was no root cause or potential root cause identified.
Observation 6
Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically, hazardous drugs, hormones, and antibiotics were produced in your firm's non-sterile suite area without providing adequate cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination. However, your firm does not have a cleaning procedure for these drug products to ensure cross-contamination does not occur. In addition, your firm places dedicated utensils in the dishwasher with non-dedicated utensils used in production. On 08/30/2018, we observed hazardous/antibiotics being produced under the same hood as non-hazardous drugs.
Inspection Jun 26, 2017: 3 observations
- Firm on the cover
- , 3265 W Mc Nab Rd Si nceru s Florida, LLC, Pomp a no Beac h, FL 33069- 4807
- FEI number
- 3012384835
- Establishment type on the cover
- 503B Out sou r c i ng Fac i l ity
- FDA district office on the cover
- At l a nt a, GA 30309
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination of drng products pmp orting to be sterile are not followed.
Specifically,
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. Specifically, your monitoring program for classified areas within the REDACTED (b)(4), including the ISO 5 laminar air flow hood and ISO 7 REDACTED (b)(4) room used to produce sterile chug products is deficient in that:
(b)(4)
(a). Viable and non-viable air and surface monitoring is only conducted on a REDACTED (b)(4) ba sis as part of room qualification activities.
(b ).Personnel monitoring is not conducted during routine production and such monitoring only includes REDACTED (b)(4) I as part of a sterile operator's aseptic processing assessment.
(c).The effectiveness of your cleaning and sanitization procedures within the cleanroom have not been demonstrated through routine REDACTED (b)(4) the cleaning process.
Observation 2
Procedures designed to assure that correct labeling and packaging materials are used for chug products are not written and followed.
Specifically, packaging and labeling procedures that describe the receipt, examination, issuance, and storage of labeling; that describe the operations involved in the packaging and labeling of drug products produced and distributed by your fnm have not been established.
Observation 3
The labels of your outsourcing facility's drug products are deficient.
Specifically,
The correct dosage form is not stated on your product label for Magnesium Sulfate Solution/50ml, a s required by section 503B(a)(10)(A).
Linked 483s whose text is not shown
- Aug 22, 2016: FDA document 99495: the PDF is a scanned image with no readable text.
State board of pharmacy records
The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PH29976 | Pharmacy | SINCERUS FLORIDA, LLC (dba SKNV) | POMPANO BEACH | Clear |
| PH29905 | Pharmacy | SINCERUS FLORIDA, LLC (dba SKNV) | POMPANO BEACH | Vol Relinquish |
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| OSP 7338 | OSP | SKNV | Pompano Beach, FL | Expired |
Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| PCN.0003722 | NONRESIDENT PHARMACY | SKNV | POMPANO BEACH, FL | INACTIVE |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0000048 | Outsourcing Facility-Distributor | Sincerus Florida, LLC (dba SKNV) | POMPANO BEACH, FL | Active |
| A9-0002440 | Non Resident Pharmacy | Sincerus Florida, LLC (dba SKNV) | POMPANO BEACH, FL | Expired |
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- Colorado State Board of Pharmacy license file
- Connecticut Department of Consumer Protection license file
- Delaware Division of Professional Regulation license file
- Florida Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.